Hanmi Pharmaceutical (CEO Lee Kwan-soon) will present its 11 studies on 4 new drugs and its Quantum Project at the American Diabetes Association's (ADA) 75th Scientific Sessions, which takes place from June 5 to 9 at Boston Convention Center, USA.
During the conference, Hanmi Pharmaceutical will release the results of Phase Two B clinical trials, which include the long-acting and weight-loss effect from a once-monthly treatment of "efpeglenatide," which is a GLP-1 family drug for diabetes.
Also, the company will also present its major studies of the Quantum Project, including a new drug "LAPSInsulin115," which is under development as a once-weekly insulin formulation, and "LAPS Insulin Combo," the combination of "LAPSInsulin115" and "efpeglenatide."
Furthermore, Hanmi Pharmaceutical will provide the result of the phase one clinical trial of "LAPSGLP/GCG," a novel long-acting GLP-1/Glucagon dual receptor agonist. Among 11 studies, the results of four studies will be orally released in the session, and another seven studies in posters.